anti-IL-20

DRUG3 trials

Sponsors

Novo Nordisk A/S

Conditions

HealthyInflammationPsoriasisRheumatoid Arthritis

Phase 1

Safety and Tolerability of Anti-IL-20 in Healthy Volunteers and Patients With Rheumatoid Arthritis

CompletedNCT00818064

Novo Nordisk A/SHealthy, Inflammation, Rheumatoid Arthritis

Start: 2008-12-31End: 2010-01-31Target: 32Updated: 2017-02-09

Safety and Tolerability of Anti-IL-20 in Subjects With Rheumatoid Arthritis

CompletedNCT01038674

Novo Nordisk A/SInflammation, Rheumatoid Arthritis

Start: 2010-02-28End: 2010-12-31Updated: 2017-02-09

First Human Dose Study of Anti-IL-20 in Psoriasis: A Study of Safety, Tolerability and Early Signals of Biologic and Clinical Effects

TerminatedNCT01261767

Novo Nordisk A/SInflammation, Psoriasis

Start: 2008-04-30End: 2011-01-31Updated: 2017-02-09

Related Papers

Differential Pharmacodynamic Effects on Psoriatic Biomarkers by Guselkumab Versus Secukinumab Correlate with Long-Term Efficacy: An ECLIPSE Substudy

JID Innovations2024-06-278 citations

First-In-Human, Phase 1, Randomized, Dose-Escalation Trial with Recombinant Anti–IL-20 Monoclonal Antibody in Patients with Psoriasis

PLoS ONE2015-08-0722 citations